Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS OXYS-I HAI versus intravenous oxaliplatin study
NL-OMON61684Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of oxaliplatin and capecitabine in intrahepatic cholangiocarcinoma (ICC) and colorectal cancer (CRC) (2 cohorts), sponsored by Erasmus MC. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
oxaliplatincapecitabine
03
Conditions
intrahepatic cholangiocarcinoma (ICC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON61684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61684.